{
    "organizations": [],
    "uuid": "0698bd8441edfd22cadaad5170d0f85b0600463b",
    "author": "",
    "url": "https://www.reuters.com/article/brief-affimed-reports-new-data-for-afm13/brief-affimed-reports-new-data-for-afm13-from-two-separate-clinical-trials-idUSASB0C3JJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Affimed Reports New Data For AFM13 From Two Separate Clinical Trials",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 40 PM / in 8 minutes BRIEF-Affimed Reports New Data For AFM13 From Two Separate Clinical Trials Reuters Staff 1 Min Read \nFeb 1 (Reuters) - Affimed Nv: \n* AFFIMED REPORTS NEW DATA FOR AFM13 FROM TWO SEPARATE CLINICAL TRIALS IN HODGKIN AND CD30-POSITIVE LYMPHOMAS \n* AFFIMED NV - ‍DATA DEMONSTRATE THAT AFM13 WAS WELL-TOLERATED​ \n* AFFIMED NV - ‍DATA DEMONSTRATE AFM13 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) DOUBLED COMPLETE RESPONSE RATE IN HODGKIN LYMPHOMA PATIENTS​ \n* AFFIMED NV - ‍EARLY DATA SUGGEST NEW OPPORTUNITY FOR AFM13 IN CD30-POSITIVE LYMPHOMA​ \n* AFFIMED NV - ‍AFM13 IS CLINICALLY ACTIVE AND WELL-TOLERATED AS MONO- AND COMBINATION THERAPY​ \n* AFFIMED NV - ‍ AFM13 IN COMBINATION WITH KEYTRUDA WAS WELL-TOLERATED WITH MOST OF ADVERSE EVENTS OBSERVED MILD TO MODERATE IN NATURE Source text for Eikon:  ",
    "published": "2018-02-01T15:39:00.000+02:00",
    "crawled": "2018-02-01T15:51:08.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "report",
        "new",
        "data",
        "afm13",
        "two",
        "separate",
        "clinical",
        "trial",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "affimed",
        "nv",
        "affimed",
        "report",
        "new",
        "data",
        "afm13",
        "two",
        "separate",
        "clinical",
        "trial",
        "hodgkin",
        "lymphoma",
        "affimed",
        "nv",
        "demonstrate",
        "afm13",
        "affimed",
        "nv",
        "demonstrate",
        "afm13",
        "combination",
        "pembrolizumab",
        "doubled",
        "complete",
        "response",
        "rate",
        "hodgkin",
        "lymphoma",
        "affimed",
        "nv",
        "data",
        "suggest",
        "new",
        "opportunity",
        "afm13",
        "affimed",
        "nv",
        "clinically",
        "active",
        "combination",
        "affimed",
        "nv",
        "afm13",
        "combination",
        "keytruda",
        "adverse",
        "event",
        "observed",
        "mild",
        "moderate",
        "nature",
        "source",
        "text",
        "eikon"
    ]
}